At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 3 enrolled
Drug / intervention
Eculizumabdrug
Likely dose
Eculizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Induction With Complement Inhibitor Eculizumab in Clinical Islet Transplantation
In Brief
A Phase 2 clinical trial evaluating Eculizumab for Diabetes Mellitus. Completed, enrolled 3 participants across 1 site.
Detailed Summary
This is a dual centre, single arm, exploratory study of the possibility to use eculizumab (Soliris) to prevent/reduce destruction of islets of Langerhans after portal infusion of the islets in patients with diabetics accepted for islet transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesSweden
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionMay 2018
Study CompletionJun 2018
TodayJul 2026
First PostedApr 4, 2016
Enrollment StartMay 15, 2016
Primary CompletionMay 1, 2018
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.2 years ago
Interventions
Eculizumabdrug
Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.